Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol

Blood (2025) 146 (Supplement 1): 5134.

https://doi.org/10.1182/blood-2025-5134

Published: 2025

Journal Articles

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Blood (2025) 146 (Supplement 1): 344.

https://doi.org/10.1182/blood-2025-344

Published: 2025

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

Blood (2023) 142 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2023-189713

Published: 2023

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141523

Published: 2020

Journal Articles

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Grazyna Stasiak, PhD, Malgorzata Zajac, PhD, Joanna Zaleska, Michal Kielbus, PhD, Jakub Czapinski, Andrzej Stepulak, MD PhD, Olga Jankowska-Lecka, PhD, Tomasz Gromek, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Bozena Sokolowska, MD PhD, Marek Hus, MD PhD, Lars Bullinger, MD PhD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 2878.

https://doi.org/10.1182/blood.V128.22.2878.2878

Published: 2016

Journal Articles

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Blood (2016) 128 (22): 213.

https://doi.org/10.1182/blood.V128.22.213.213

Published: 2016

Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 1685.

https://doi.org/10.1182/blood.V128.22.1685.1685

Published: 2016

Journal Articles

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

Krzysztof Giannopoulos, MD PhD, Malgorzata Zajac, PhD, Olga Jankowska-Lecka, PhD, Joanna Zaleska, Joanna Purkot, Tomasz Gromek, MD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Marek Hus, MD PhD, Lars Bullinger, MD

Blood (2015) 126 (23): 2590.

https://doi.org/10.1182/blood.V126.23.2590.2590

Published: 2015

Journal Articles

Purine Analogues Based Induction Regimen Followed By Allo-HSCT Is An Effective Treatment Modality Of Philadelphia Chromosome-Positive Acute Myeloid Leukemia-Retrospective Analysis Of Polish Adult Leukemia Group (PALG)

Agnieszka Wierzbowska, MD, PhD, Anna Szmigielska-Kaplon, MD, PhD, Agnieszka Pluta, MD, PhD, Ewa Wawrzyniak, PhD, Sebastian Grosicki, MD, Grzegorz Helbig, MD, PhD, Wanda Knopinska-Posluszny, MD, PhD, Tomasz Gromek, MD, PhD, Ilona Seferynska, MD, PhD, Ewa Lech-Maranda, Jerzy Holowiecki, Tadeusz Robak

Blood (2013) 122 (21): 1461.

https://doi.org/10.1182/blood.V122.21.1461.1461

Published: 2013

Journal Articles

Expression and Prognostic Significance of MDR and IAP -Family Genes in Patients with Acute Myeloid Leukemia

Maria B. Cioch, Janusz Kocki, Katarzyna Kotwica, Tomasz Gromek, Anna Dmoszynska

Blood (2008) 112 (11): 3989.

https://doi.org/10.1182/blood.V112.11.3989.3989

Published: 2008

Journal Articles

JAK2 Mutational Status, Hemostatic Risk Factors and Thrombophilic Factors in Essential Thrombocythemia (ET) Patients

Bozena Sokolowska, MD, PhD, Aleksandra Nowaczynska, PhD, Ksenia Bykowska, PhD, Sylwia Chocholowska, PhD, Katarzyna Wejksza, PhD, Adam Walter-Cronack, MD, PhD, Martyna Kandefer-Szerszen, PhD, Tomasz Gromek, MD, PhD, M. Anna Kowalska, PhD, Anna Dmoszynska, MD, PhD

Blood (2008) 112 (11): 4542.

https://doi.org/10.1182/blood.V112.11.4542.4542

Published: 2008

Journal Articles

Fibrinolytic Activity in Patients with Essential Thrombocythemia.

Bozena Sokolowska, MD, PhD, Aleksandra Nowaczynska, MSc, Katarzyna Wejksza, MSc, Adam Walter-Croneck, MD, Martyna Kandefer-Szerszen, PhD, Tomasz Gromek, MD, M. Anna Kowalska, PhD, Anna Dmoszynska, MD, PhD

Blood (2007) 110 (11): 3223.

https://doi.org/10.1182/blood.V110.11.3223.3223

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia Group

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year Report

Clinical and Biological Role of Accumulation of the NPM-1 Splice Variant R2 in AML, MDS and sAML

Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Accumulation of the NPM-1 Splice Variant R2 Accompanies AML Development

Purine Analogues Based Induction Regimen Followed By Allo-HSCT Is An Effective Treatment Modality Of Philadelphia Chromosome-Positive Acute Myeloid Leukemia-Retrospective Analysis Of Polish Adult Leukemia Group (PALG)

Expression and Prognostic Significance of MDR and IAP -Family Genes in Patients with Acute Myeloid Leukemia

JAK2 Mutational Status, Hemostatic Risk Factors and Thrombophilic Factors in Essential Thrombocythemia (ET) Patients

Fibrinolytic Activity in Patients with Essential Thrombocythemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only